突出-89放射性药物超越抗体的新研究趋势
Janie Duvenhage1, Maryke Kahts2, Beverley Summers2
1Preclinical Imaging Facility, Nuclear Medicine Research Infrastructure NPC, Pretoria, South Africa; Radiochemistry, The South African Nuclear Energy Corporation (Necsa), Pelindaba, South Africa.
Seminars in nuclear medicine
|October 27, 2024
概括
-89 (89Zr) 能够在几天内进行敏感的分子成像. 本综述探讨了超越抗体的新型89Zr放射性药物,包括和纳米颗粒,用于临床前和临床使用.
科学领域:
- 核医学是一种核医学.
- 放射化学 放射化学是指辐射化学.
- 分子成像学分子成像学
背景情况:
- -89 (89Zr) 是一种发射正子的放射性同位素,由于其半衰期为3.27天,因此非常适合用于纵向分子成像.
- 89Zr标记的单克隆抗体 (89Zr-mAb) 是分子成像中的已知工具.
- 研究正在扩展到超出mAbs.的各种89Zr放射性药物.
研究的目的:
- 审查非mAb 89Zr放射性药物的现状和挑战.
- 突出在临床前和临床环境中的新兴应用.
- 讨论新型分子成像剂的潜力.
主要方法:
- 临床前和临床研究的文献综述.
- 分析放射性标记策略和成像性能.
- 讨论开发和应用中的挑战.
主要成果:
- 在开发89Zr标记蛋白质,,纳米粒子和细胞方面取得了重大进展.
- 在追踪各种目标时,具有高灵敏度,分辨率和特异性的潜力.
- 确定了生产,稳定性和临床翻译方面的挑战.
结论:
- 非mAb 89Zr放射性药物为分子成像提供了有希望的替代品.
- 需要进一步的研究来克服开发和临床翻译的障碍.
- 这些新型药物扩大了89Zr在各种生物医学应用中的实用性.
更多相关视频
相关概念视频
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
89
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
89